$0.56
8.37% today
NYSE, Apr 02, 09:20 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock price

$0.52
-0.10 16.08% 1M
-0.12 18.46% 6M
-0.08 13.57% YTD
-0.26 33.01% 1Y
-2.53 83.00% 3Y
-2.58 83.27% 5Y
-3.70 87.71% 10Y
NYSE, Closing price Tue, Apr 01 2025
-0.05 9.03%
ISIN
US9286611077
Symbol
VNRX
Sector

Key metrics

Market capitalization $49.77m
Enterprise Value $49.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 38.07
P/S ratio (TTM) P/S ratio 38.58
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 97.50%
Revenue (TTM) Revenue $1.29m
EBIT (operating result TTM) EBIT $-29.98m
Free Cash Flow (TTM) Free Cash Flow $-14.48m
Cash position $5.41m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 36.28
EV/Sales forward 35.82
Short interest 0.67%
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast VolitionRX:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast VolitionRX:

Buy
100%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.29 1.29
98% 98%
100%
- Direct Costs 1.34 1.34
1% 1%
104%
-0.06 -0.06
92% 92%
-5%
- Selling and Administrative Expenses 13 13
13% 13%
1,039%
- Research and Development Expense 15 15
15% 15%
1,177%
-29 -29
16% 16%
-2,220%
- Depreciation and Amortization 1.34 1.34
1% 1%
104%
EBIT (Operating Income) EBIT -30 -30
15% 15%
-2,324%
Net Profit -30 -30
12% 12%
-2,316%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
Seeking Alpha
one day ago
VolitionRx Limited (NYSE:VNRX ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President & Chief Executive Officer Terig Hughes - Chief Financial Officer Andrew Retter - Chief Medical Officer Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Brok...
Neutral
PRNewsWire
2 days ago
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024.
Neutral
PRNewsWire
5 days ago
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer HENDERSON, Nev. , March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYS...
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Founded 1998
Website www.volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today